Baxter 20 mEq/L Potassium Chloride in 0.9% Sodium Chloride Injection USP 1000 mL VIAFLEX Plastic Container

Description

Baxter 20 mEq/L Potassium Chloride in 0.9% Sodium Chloride Injection USP 1000 mL VIAFLEX Plastic Container

Baxter 20 mEq/L Potassium Chloride in 0.9% Sodium Chloride Injection USP 1000 mL VIAFLEX Plastic Container The intravenous administration of Potassium Chloride in 0.9% Sodium Chloride Injection, USP can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injection. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injection. In patients with diminished renal function, administration of Potassium Chloride in 0.9% Sodium Chloride Injection, USP may result in sodium or potassium retention. Potassium salts should never be administered by IV push.

For patients receiving potassium supplement at greater than maintenance rates, frequent monitoring of serum potassium levels and serial EKGs are recommended. Studies with Potassium Chloride in 0.9% Sodium Chloride Injection, USP have not been performed to evaluate carcinogenic potential, mutagenic potential or effects on fertility.

Hypersensitivity/infusion reactions, including anaphylaxis, have been reported with other products containing potassium chloride and sodium chloride. Stop the infusion immediately if signs or symptoms of hypersensitivity/infusion reactions develop. Appropriate therapeutic countermeasures must be instituted as clinically indicated (see CONTRAINDICATIONS).

For more Baxter Product click here.